sec filing - novogen yale uni joint venture , page-5

IMO this partnership with Yale is the core business that has the cancer drug technology and IP (Novogen)and now the delivery technology inclusive of ovarian stem cell specialisation (Yale).

A perfect fit end to end.

This core business and the way it is setup will then partner with a major pharmaceutical and major investor to fund development and progress.

This is where the roadshows in December fit in.